It has been supposed in de novo AML that malignant transformby the expression of lineage-specific and/or lineage-associated ation occurs at the level of committed progenitors. Recent data cell surface molecules acquired on different maturational of our group and others provide evidence that in AML malig- genetics that flow-sorted CD34 + /CD38 − stem cell populations
gets lost.
CD34
؉ stem cells can be further subdivided by the expression 18, 19 On leukemic blasts the immunopheno-
AML and four MDS). Six of them displayed clonal karyotype
typic profile of normal immature hematopoietic progenitors abnormalities at the time of first diagnoses in the native bone marrow (5q؊; 5q؊ and complex abnormalities; ؉8; inv(16) and characterized by the expression of CD34, CD38 and HLA-DR ؉8; i(17q) and ؊21; i(21q)). We used CD117, the receptor for the is well conserved. 20 Blasts from a patient with AML M1, stem cell factor (also KIT oncogene) as a new cellular surface injected into SCID mice were able to induce the clinical and
marker. CD34
؉
/CD117
؎ stem cell subpopulations were examhematologic features of AML 21 although it has been reported ined in two patients with AML and three patients with MDS. We by others that CD34 − blasts also have the potential for leukefound leukemic stem cells in every type of stem cell subpopulmia-induction in SCID mice. 22 In 1995, it was independently genetics that flow-sorted CD34 + /CD38 − stem cell populations
In three patients a mosaic of normal and abnormal metaphases
harbor clonal leukemia-specific cytogenetic abnormalities.
2, 3, 6 was found in the highly purified stem cell subpopulations. We
Taken together, these data suggest that the leukemogenic Our data in acute myeloid leukemia showed that the in panoptic staining. The classification of acute leukemias sugmajority of patients had a mosaic of normal and abnormal gests an arrest of maturation at a specific stage of differenmetaphases in this subcompartment of hematopoietic stem tiation, due to malignant transformation of the presumed norcells. In analogy to normal hematopoiesis we reasoned that mal counterparts. 1 However, very recent contrasting results further subdivision might be achieved through analysis of the from the past year show that in the vast majority of acute stem cell factor receptor (CD117). This antigen is present on myeloid leukemias (AML) and acute lymphoblastic leukemias 50% of acute myeloid leukemias.
23
(ALL) transforming genetic events occur at the level of immaIn this article, we present data on the cytogenetic analysis ture progenitors, [2] [3] [4] [5] [6] similar to previously obtained data from of CD34 + /CD117 ± subpopulations from five patients with AML chronic myeloid leukemia (CML) and myelodysplastic synand MDS in comparison to CD34 + /CD38 ± subpopulations dromes (MDS). 7, 8 from 15 patients of which data of three patients were not The ability to identify and characterize stem cells by funcpublished before. tion 9, 10 and specific surface molecules 11 has provided an access to stem cell biology in normal hematopoiesis and malignant disorders. Stem cells express a characteristic cell Materials and methods surface antigen classified as CD34.
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The population of CD34 + cells can be further subdivided cedures according to their immunophenotype. Patients were for successful karyotyping was 500 for classical cytogenetics and 210 for molecular cytogenetics (FISH). admitted to the Department of Internal Medicine at the University of Gö ttingen (Gö ttingen, Germany). Diagnosis and Two out of the eight patients (Nos 2 and 7) had a normal karyotype in the unsorted bone marrow at diagnosis. In both classification of AML and MDS were based on light microscopy of Pappenheim-stained slides, and on cytochemcases only normal metaphases were found in the sorted subpopulations. In the remaining six patients clonal karyotype ical reaction with periodic acid schiff (PAS), myeloperoxidase, and esterase. Slides were reviewed by two independent hemaabnormalities (5q− + complex anomalies, inv(16) with +8, i(17q), i(21q), 5q− alone, +8 alone) were demonstrable in the tologists according to the criteria of the French-AmericanBritish (FAB) classification. 15, 24 diagnostic bone marrow (further details are given in Table 1 ). In eight patients (four AML: M0, M2, M4, M4Eo, and four MDS: one secondary RA, two de novo RA, one de novo RAEB) the cellular and metaphase yield after the sort was sufficient CD34 +
/CD38
− population to perform cytogenetic analysis.
The cellular yield after sort was 25 × 10 3 in patient 1, 2.3 × 10 3 in patient 2, and 10 × 10 3 in patient 3. In patient 1
Immunophenotyping and cell sorting with a secondary MDS, CD34 + /CD38 − and CD34 + /CD38 + cells were sorted together in one fraction. In the highly purImmunophenotyping was performed at diagnosis by multiified stem cell population all five abnormal cell clones found parameter flow cytometry using a whole blood lysis method in the unsorted bone marrow were demonstrable in the CD34
+ and a set of monoclonal antibodies against myeloid and progenitor cell population. In the other two patients metalymphoid lineage-associated antigens. 25 The early maturation phases were not available from the CD34 + /CD38 − cells after pathway was characterized with monoclonal antibodies sort. against CD34 and CD38 as described. 3 In the second set of experiments, mononuclear cells were stained simultaneously with the anti-CD34 antibody HPCA-2 (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA), conjugated
+ population to FITC (fluorescein isothiocyanate), and the anti-CD117 antibody 95C3 (Coulter Immunotech, Hamburg, Germany), conIn this population the cellular yield was 215 × 10 3 and jugated to PE (phycoerythrin). A gate was set on the blast 400 × 10 3 , respectively. In patient 2 corresponding to the population. For isolation of subpopulations by cell sorting, unsorted bone marrow specimen only normal metaphases fresh bone marrow aspirates were used in all eight patients.
were found. In patient 3 only abnormal metaphases with Processing of the cells and the sort procedure were performed inv(16) and trisomy 8 as secondary abnormality were as described. 3 A minimum of 50 cells of each subpopulation observed in the sorted population. was sorted with a purity of 96% to 98%.
CD34

+
/CD117
− population In vitro culturing and classical and molecular cytogenetics This subpopulation was examined in five patients. The cellular The FACS-isolated cells were incubated with a cytokine-cockyield after sort ranged between 0.21 × 10 3 and 10 × 10 3 with tail (recombinant human (rh) granulocyte colony-stimulating a median of 3.1 × 10 3 . Patient 7 had a normal karyotype in factor 100 U/ml (Amgen, Thousand Oaks, CA, USA), glycosylhis unsorted bone marrow as well as in his sorted stem cells. ated rh granulocyte-macrophage colony-stimulating factor
In the remaining four patients identical clonal karyotype 100 U/ml (Behringwerke, Marburg, Germany), rh interleukinabnormalities were demonstrable in the unsorted specimens 3 100 U/ml (Behringwerke), rh erythropoietin 1 U/ml as well as in the CD34 + /CD117 − stem cell subpopulations. (Boehringer, Mannheim, Germany), and rh stem cell factor Two patients (Nos 6 and 8) displayed a mosaic of normal and 50 ng/ml (Genzyme, USA)) in a fully humidified atmosphere abnormal cells (AN-karyotype) in their sorted stem cells. In containing 5% CO 2 at 37°C, processed for karyotyping or patient 8 only interphase cells were available after the cell fluorescence in situ hybridization (FISH) and cytogenetically sort, which were analyzed by fluorescence in situ hybridizclassified as described. 3 The number of metaphases analyzed ation, using a centromeric probe for chromosome 8. 
− interphase-stem cell of on 77 sorted interphase cells (Table 1) . patient 8 (trisomy 8) with three fluorescent signals.
Results
CD34
+ /CD117 + population
We successfully performed classical and molecular cytogenetic analysis of highly purified flow-sorted CD34 + subpop-CD34 + /CD117 + cells were sorted in five patients. The cellular yield was very low and ranged between 0.05 × 10 3 and ulations in eight patients (four AML, four MDS). In three cases the expression of CD38 was used as a marker for further sub-100 × 10 3 with a median of 0.4 × 10 [19] no meta, no metaphases available; [ ], number of metaphases analyzed; NN, only normal metaphases; AA, only abnormal metaphases; AN, mosaic of abnormal and normal metaphases; (Fl), analyzed by fluorescence in situ hybridization; S-MDS, secondary MDS; RA, refractory anemia; RAEB, refractory anemia with excess of blasts.
Table 2
Overview of our cytogenetic data of CD34 + sorted stem cell subpopulations (eight patients from this article and 13 patients published elsewhere (Ref. stem cell subpopulations available) clonal chromosome abnormalities were demonstrable in the stem cell subpopulaDiscussion tions irrespective of the type of chromosome abnormality, the phenotype of the bulk leukemic population (FAB-type) the Together with data of 13 patients with AML published elsewhere, 3 we were successful in performing cytogenetic investisize of the CD34-positive stem cell population and the primary or secondary character of the disease. Especially in the gations in highly purified, flow-sorted CD34
+ stem cell subpopulations in 21/49 patients with MDS and AML (see Table  cases of M4Eo with inversion 16 these observations were quite unexpected, since it seemed obvious that in these patients 2). In five patients a normal karyotype was observed in the unsorted bone marrow. The analysis of CD34 + sorted subpopmalignant transformation occurs at the level of myelomonocytic committed progenitors. Even more remarkable are our ulations in these cases failed to detect karyotype abnormalities and also confirmed the normal karyotype in the stem cell findings in five patients (5 and 13 in Ref. 3 , and 1, 3 and 4 in this article) which argue for an occurrence not only of pricompartment. It can be supposed that in these patients molecular events on a submicroscopic level were responsible for mary, transforming defects but also of secondary, progressionassociated abnormalities at the level of immature progenitors. malignant transformation.
Sixteen patients displayed a large variety of cytogenetic Case 1 is especially interesting since in this patient with a secondary MDS all five abnormal cell clones consisting of a abnormalities (Table 3) . Our recent findings confirm prior observations that in every informative case (abnormal karyostem line with a 5q− chromosome as initial abnormality and four different depending subclones were demonstrable in the type in the unsorted material and metaphases in the sorted
Cytogenetics of CD34
+ cells in AML and MDS D Haase et al 677 Table 3 Accumulated published data on stem cell involvement in AML and MDS unsorted as well as in the highly purified flow-sorted CD34 + PGK gene. It was concluded from the data that in AML M3 the leukemogenic event does not take place in the stem cell population, providing clear evidence that karyotype evolution and thus the dynamic process of disease progression CD34 + /CD38 − stem cells but is demonstrable in the more committed CD34
+ /CD38 + population. Mehrotra et al 2 anatakes place in the stem cell compartment. This observation furthermore implies that genetic instability -the prerequisite lyzed sorted stem cell subpopulations in 15 patients with AML harboring numerical karyotype abnormalities in their unsorted for an accumulation of (cyto)genetic abnormalities -occurs at the level of CD34 + stem cells. diagnostic bone marrow biopsies by FISH. In 15 of 15 cases they were able to demonstrate the respective numerical Our results demonstrate that even tiny stem cell subpopulations with a cellular yield after cell sort of under 1000 cells abnormality in the sorted immature stem cells. Together with our data, 20 different karyotype abnormalities were found can be successfully karyotyped. This observation can be explained by the outstanding response of the stem cells to the within CD34 + stem cell subpopulations up to now. This is a strong argument for the hypothesis that malignant transformcytokine cocktail chosen by us. 3 The proliferative potential of FACS-isolated CD34 + lineage-negative stem cells is compatation in AML at the level of immature stem cells is the rule rather than the exception which had been assumed up to now. ible with the successful initiation of leukemia in SCID mice by inoculation with highly purified immature progenitor cells. 21 The data of Turhan and colleagues 32 however shed light on the possibility that distinct leukemias with a very special In 10 of 16 patients with abnormal stem cells an accompanying population of normal cells was demonstrable biology might be excluded from what seems to be a common pathway in leukemogenesis. However, data of this group on (details in Table 2 ). Further sort and genotyping research should focus on strategies for the discrimination between northe lack of PML-RARA fusion transcripts in CD34 + /CD38 − cells need further confirmation. Two other authors have published mal and abnormal stem cells. Our first attempt to follow this strategy was to use the coexpression of CD117 as a putatively corresponding data on stem cell involvement in acute lymphoblastic leukemia (ALL). From their results both came to the discriminating element. However, in this respect our results are disappointing since neither the CD34 + /CD117 − nor the conclusion that as in AML in a considerable number of patients with ALL, the malignant transformation occurs at the CD34 + /CD117 + populations were free of leukemia-associated abnormalities in the informative cases (Table 2) . Further data immature CD34 + /lineage-negative stem cells. 4, 5 Considering the total of all rare but corresponding data (M3 are needed to confirm our preliminary results especially for the CD34 + /CD117 + populations which seem to be difficult might be an exception) of stem cell genetics in hematologic malignancies an alternative model of leukemogenesis has to to analyze.
The vast majority of published data from other groups is be discussed (Figure 2 ). The conservative model of leukemogenesis is based on the dogma that the leukemic phenotype based on indirect evidence for a stem cell involvement in malignant transformation in hematologic malignancies. Most is a reflection of the level of the hematopoietic hierarchy at which the leukemogenic genetic defect occurs. A new model information was derived from FISH and/or cytogenetic analyses of immunophenotypically characterized cells from differtaking into account recent stem cell data could be derived from the hypothesis that the genetic defect regularly occurs at ent cell lineages, [26] [27] [28] [29] or from combining morphology and FISH. 30 Another group examined Ig heavy chain gene the level of immature pluripotent stem cells and determines the differentiation program of the affected cell clone. Clonal rearrangements in lymphoid and myeloid cells from patients with mixed lineage de novo acute leukemias. Their results abnormalities are only detectable in a distinct expanding leukemic cell clone if they provide a survival benefit. If not, the were compatible with a clonal gene rearrangement at the level of pluripotent stem cells. 31 Recently, independent from us two affected cells might undergo apoptosis or remain in an interphase status. Thus the paradox could be explained that groups have analyzed highly purified, flow-sorted stem cells (Table 3) . Turhan et al 32 examined CD34 + /CD38 − and most clonal abnormalities occur at the level of immature stem cells but not all of them can be observed in any cell lineage. CD34 + /CD38 + stem cell subpopulations for the presence of the PML-RARA fusion transcript in three patients with promyeHowever, it also has to be taken into account that methodological problems might hinder the detection of abnormalities locytic AML (M3-subtype) by reverse transcriptase-polymerase chain reaction (RT-PCR). In two patients clonality analysis was in different lineages. These results have substantial implications for the monitoradditionally performed using the BstXI polymorphic site of the demonstrating residual leukemic cells in the retransfused stem cell autograft. 34 Therapeutically these results have two consequences. On the one hand evidence is accumulating that in acute leukemia the stem cell has to be the target of high-dose chemotherapy and should not be protected from it if curative strategies are followed. On the other hand, our data shed light on the heterogeneity of the stem cell compartment with leukemic and potentially normal counterparts. Future studies should focus on how to discriminate these two stem cell subpopulations.
